Double blind placebo controlled crossover study of deae dextran in hyperlipoproteinemia secondary to non insulin dependent diabetes mellitus
Galeone, F.; Giuntoli, F.; Brunelleschi, G.; Saba, P.
Acta Therapeutica 16(4): 313-322
The effects of diethylaminoethyl-dextran (DEAE-D) and diet on plasma lipids and body weight in 20 diabetic patients with type IV hyperlipoproteinaemia were studied in a double-blind placebo-controlled crossover study. Both dietary prescription (1.500 Kcal in men and 1.200 Kcal in women) and placebo for 90 days brought about a slight decrease in plasma triglycerides (TG) (-6%) and glucose (-3%). However, when DEAE-D 3 g/day was added to the diet for 90 days, total cholesterol and low density lipoprotein cholesterol showed a statistically significant decrease of 20 and 26%, respectively. Plasma TG decreased a further 23%. After DEAE-D, significant increases in high density lipoprotein cholesterol (+14%) and apoprotein A1 (+31%) were also recorded, while apoprotein B was slightly decreased (-9%). A statistically significant reduction in plasma glucose (-9%) and glycosylated haemoglobin (HbA1) (-4%) was observed in the DEAE-D treated group, the effects of DEAE-D on plasma lipids and glucose were maintained after replacement of the drug with placebo, thus excluding the possibility of a "rebound effect" after the withdrawal of the drug. Finally, no untoward side effects were recorded during the study.